Valuation: ALLOVIRPAR

Market Cap 49.21M 44.17M 40.78M 36.98M 69.12M 4.67B 69.97M 489M 194M 2.45B 185M 181M 7.77B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -62M -57.25M -51.91M -97.02M -6.56B -98.21M -686M -273M -3.44B -259M -254M -10.91B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+3.33%
Current month-81.04%
Current year-81.04%
3 years 1.78
Extreme 1.78
57.15
5 years 1.78
Extreme 1.78
575.23
10 years 1.78
Extreme 1.78
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -171M -158M -143M -267M -18.09B -271M -1.89B -751M -9.48B -715M -699M -30.06B -58.77M -52.75M -48.7M -44.16M -82.54M -5.58B -83.56M -584M -232M -2.93B -221M -216M -9.28B
Net Debt -157M -140M -130M -118M -220M -14.87B -223M -1.56B -618M -7.79B -588M -575M -24.71B -118M -106M -98.03M -88.89M -166M -11.24B -168M -1.18B -467M -5.89B -444M -435M -18.68B
Projected Income Statement - Annual - ALLOVIRPAR
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
27/10/26 US$1.860 +3.33%
26/10/26 US$1.800 -3.74%
23/10/26 US$1.870 -6.03%
22/10/26 US$1.990 -1.49%
21/10/26 US$2.020 -2.42%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock